Search Results
Your search for early matches 10012 pages
Showing 1151 - 1200ASCO Congratulates 2023 Special Awards Recipients
ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care with the Society’s highest honors at the 2023 ASCO Annual Meeting in Chicago. Hear from select award recipients at the...
Involvement in SWOG and JCO Leads to a Fulfilling Career as a Leader in Oncology
Jonathan W. Friedberg, MD, MMSc, Director of the James P. Wilmot Cancer Institute, grew up in a suburb of Milwaukee. While his school friends were attending camp, he spent his summers working on the family farm. “Perhaps the hardest work I’ve ever done was haying on a hot, humid night in July,...
The Second-Generation Son of Greek Immigrants, the First to Go to College, Becomes a Leader in Sarcoma Research and Treatment
George D. Demetri, MD, FASCO, Director of the Sarcoma Center at Dana-Farber Cancer Institute, and Professor of Medicine and Co-Director of the Ludwig Center at Harvard, was born in Hyde Park, a town along the Hudson River in New York. When Dr. Demetri was growing up there, it was known for three...
HER3-Targeting Antibody-Drug Conjugates Show Encouraging Results in Breast Cancer Subtypes
Early-phase data from the SOLTI TOT-HER3 and ICARUS-BREAST01 trials suggest that the novel HER3-directed antibody-drug conjugate patritumab deruxtecan may have beneficial activity in patients with hormone receptor–positive/HER2-negative and triple-negative breast cancer subtypes, according to...
Mourned and Missed
The respected members of the oncology community listed here are among some of those who passed away in 2022–2023. The ASCO Post remembers them, their lives, and their contributions to cancer research and treatment. Robert J. Gillies, PhD Moffitt Cancer Center and the global research community lost ...
A Leader in Oncology From Humble Beginnings Never Forgets Life Lessons Learned Along the Way
In December 2019, Robert A. Winn, MD, became the second Black physician to lead a National Cancer Institute (NCI)-designated comprehensive cancer center when he took the helm of the Virginia Commonwealth University (VCU) Massey Cancer Center. Dr. Winn’s basic science research, which has been...
A Love of Immunology Leads to a Notable Career in Dermatology, With a Focus on Melanoma Research and Treatment
Caroline Robert, MD, PhD, Head of the Dermatology Unit at Gustave Roussy and Co-Director of the Melanoma Research Unit at INSERM 981 Paris-Sud University, was born and reared in Paris. “I didn’t have a vocation for medicine when I was a kid; I wanted to be an archeologist. I’m not from a medical...
Inspired by an Uncle Who Was a Compassionate Family Doctor, This Nonagenarian Continues a Renowned Career in Hematology
Today is the era of the multidisciplinary oncology care approach, cancer staging facilitates precision in documenting disease extent, all of which improved the quality of patient care. However, in the United States, the Rai staging system is still the most commonly used clinical staging system for...
From a Small Town in North Carolina, a Young Girl Finds Her Calling in Battling Inequity in Cancer Care
Manali Patel, MD, MPH, Associate Professor of Medicine (Oncology) at Stanford University, grew up in Shelby, a small town in the textile and farming community of Western North Carolina, among mill workers and other blue-collar laborers. The daughter of Indian immigrants, Dr. Patel’s early life was...
A Free-Spirited Childhood on a Dairy Farm, Where Books and Science Experiments Were Encouraged
Susan K. Parsons, MD, MRP, Professor of Medicine and Pediatrics at Tufts University School of Medicine and Founding Director of the Reid R. Sacco Adolescent and Young Adult Program for Cancer and Hereditary Blood Disorders at Tufts Medical Center, grew up on a working dairy farm in Sharon Springs,...
FDA Approves Flotufolastat Fluorine-18 Injection, First Radiohybrid PSMA-Targeted PET Imaging Agent for Prostate Cancer
On May 30, the U.S. Food and Drug Administration (FDA) approved the optimized, high-affinity radiohybrid prostate-specific membrane antigen (PSMA)-targeted positron-emission tomography (PET) imaging agent flotufolastat fluorine-18 (Posluma). Flotufolastat F-18 is indicated for PET imaging of...
Incidence of Colorectal, Lung, and Breast Cancers May Be Rising Due to COVID-19–Related Screening Delays
Delays in cancer screenings during the COVID-19 pandemic may have resulted in lower reported incidences of colorectal, lung, and breast cancers, reflecting potentially high rates of undiagnosed cancer and later-stage diagnoses, according to a new study published by Romatoski et al in the Journal of ...
ASCO Congratulates 2023 Special Awards Recipients
ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care around the world with the Society’s highest honors at the 2023 ASCO Annual Meeting in Chicago. Hear from select award...
Disparities in Cancer Care: A Bangladeshi Perspective
The fight against cancer has made remarkable progress worldwide over the past decade. Through corporate investment in research and technology, the incidence of cancer and death rates in developed nations have steadily declined. The number of people living longer and fuller lives after a cancer...
Northwell Launches Cancer Care Direct, Pairing Nurse Navigators With Patients Through Spectrum of Care
Knowing the health-care system is complex and often creates anxiety for patients newly diagnosed with cancer, the Northwell Health Cancer Institute has launched Cancer Care Direct, a comprehensive program to connect patients with clinical registered nurse navigators who can provide expert guidance...
Surviving, but Not Always Thriving, After Cancer
As discussed in Part I of this special feature on cancer survivorship, there are now more than 18 million cancer survivors in the United States, and that number is expected to grow to 26 million by 2040.1 However, most of those survivors—at least two-thirds—either cured or in remission or living...
Survival in Patients With Neuroblastoma on Reduced Therapy as a Result of Change in COG Risk Stratification
In an analysis recently reported in the Journal of Clinical Oncology,1 Bender et al found that “excellent” survival outcomes were achieved in patients receiving reduced treatment for neuroblastoma as a result of reassignment to intermediate risk from high risk based on a change in the minimum age...
Surviving, but Not Always Thriving, After Cancer
The improvement in cancer survival rates since President Richard M. Nixon signed the National Cancer Act of 1971 into law is staggering. The legislation further committed the United States to greater investments in cancer-focused research to drive down the rates of cancer diagnoses, boost patient...
American College of Surgeons Evaluates the Impact of COVID-19 Pandemic on National Cancer Database Reporting
New research from the American College of Surgeons (ACS) outlines significant ways that the COVID-19 pandemic destabilized usual patterns of cancer care, as reported in the National Cancer Database (NCDB). The NCDB is one of the largest cancer registries in the world and is used by thousands of...
Radiation Oncology Workforce Expected to Remain Stable Through 2030
A new analysis of the U.S. radiation oncology workforce projects a relative balance between the supply of radiation oncologists and the demand for radiation therapy services through 2030.1 The report was produced by Health Management Associates (HMA), a consulting firm commissioned by the American...
Playing a Doctor in a School Play Sparked an Early Desire to Become a Real Doctor for Sibylle Loibl, MD, PhD
For this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Sibylle Loibl, MD, PhD, Chair of the German Breast Group (GBG) and Chief Executive Officer of the GBG Forschungs GmbH. Professor Loibl, Associate Professor of Obstetrics and Gynecology ...
Prevalence of Functional Limitations in U.S. Cancer Survivors
In a study reported in a research letter in JAMA Oncology, Patel et al found that the prevalence of self-reported functional limitations in U.S. cancer survivors increased between 1999 and 2018. Study Details The analysis included adults in the 1999 to 2018 National Health Interview Survey (NHIS)...
Genetic Sequencing May Identify Cancers Often Missed by Traditional Screening Guidelines
Whole-exome sequencing of a large database identified carriers of mutations associated with hereditary cancer syndromes (ie, hereditary breast and ovarian cancers and Lynch syndrome). What was surprising was that among those carriers, about 40% did not satisfy the existing National Comprehensive...
Expert Point of View: Stephen Lam Chan, MD
Invited discussant of the IMbrave050 trial, Stephen Lam Chan, MD, of Chinese University of Hong Kong, put the study into context. “After curative treatment, recurrence remains a big problem [in patients with hepatocellular carcinoma at high risk of disease recurrence following resection or...
IMbrave050 Trial: Adjuvant Regimen of Atezolizumab Plus Bevacizumab in Resectable Hepatocellular Carcinoma
Adjuvant treatment with the combination of atezolizumab and bevacizumab achieved a statistically significant and clinically meaningful improvement in recurrence-free survival compared with active surveillance alone in patients with high-risk hepatocellular carcinoma following curative-intent...
Israeli Surgical Oncology Leader Dov Zippel, MD, Considers the Evolving Landscape of Cancer Care in a Small Nation
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Dov Zippel, MD, a surgical oncologist at Sheba Medical Center in Tel Hashomer, Israel, where he is Head of the Meirav Breast Center. Dr. Zippel is the current President of ...
Novel Bispecific Antibody for Multiple Myeloma Shows High Response Rates in Early Trial
The bispecific antibody REGN5459 achieved a 90.5% overall response rate when given at the two highest doses in patients with relapsed or refractory multiple myeloma, according to the results of a phase I/II clinical trial.1 Although preliminary, the results of this first-in-human trial for the...
Assay Prediction of pCR in Patients With HER2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab
In an analysis reported in JAMA Oncology, Waks et al found that the HER2DX assay performed well in predicting the likelihood of pathologic complete response (pCR) in patients with early HER2-positive breast cancer receiving de-escalated neoadjuvant treatment with paclitaxel, trastuzumab, and...
Late Major Surgical Intervention in Survivors of Childhood Cancer
In an analysis from the Childhood Cancer Survivor Study (CCSS) reported in The Lancet Oncology, Dieffenbach et al found that childhood cancer survivors had a heavy cumulative burden of late major surgical interventions. Study Details The study involved data from the CCSS on 5-year survivors of...
Exercise, Wellness Interventions in Early Breast Cancer Demonstrate Measurable Benefits—Even Economic Ones
Specialized exercise and wellness programs significantly elevated physical well-being and quality of life among patients with breast cancer while reducing the use of health-care resources in new research presented at the 2023 American Society of Breast Surgeons Annual Meeting. In one multicenter...
Specialist Palliative Care for Patients Undergoing Major Abdominal Surgery for Cancer
In a single-center trial reported in JAMA Surgery, Shinall et al found that specialist palliative care did not improve quality of life or survival vs usual care in patients undergoing nonpalliative major abdominal surgery for cancer. Study Details In the trial, 235 patients scheduled for specified...
Association Between Overweight/Obesity and Risk of Gastrointestinal Cancer
Researchers have found that individuals in early and middle adulthood who have a body mass index (BMI) indicating that they have overweight or obesity may be at an increased risk of developing gastrointestinal cancer, according to a new study published by Loomans-Kropp and Umar in JAMA Network...
Augmented Early Intensification and Higher Consolidation Methotrexate Dosing Show No Benefit in Childhood ALL
Results of the Intercontinental-Berlin-Frankfurt-Münster 2009 trial in childhood acute lymphoblastic leukemia (ALL) were reported in the Journal of Clinical Oncology by Campbell et al. Findings included no benefit of augmented early intensification in intermediate-risk or high-risk patients and no...
Trastuzumab/Pertuzumab Plus Neoadjuvant Paclitaxel or Endocrine Therapy in Hormone Receptor–Positive, HER2-Positive Early Breast Cancer
In a German phase II trial (WSG-TP-II) reported in JAMA Oncology, Gluz et al found that the addition of neoadjuvant paclitaxel monotherapy to trastuzumab/pertuzumab resulted in a higher pathologic complete response (pCR) rate in patients with hormone receptor–positive, HER2-positive early breast...
Does Prediagnosis Smoking Cessation Improve Overall Survival in Patients With NSCLC?
In a cohort study reported in JAMA Network Open, Wang et al found that overall survival in patients with non–small cell lung cancer (NSCLC) who stopped smoking prior to their cancer diagnosis was better than overall survival among those who were current smokers at the time of their diagnosis. Study ...
Patients With Cervical Cancer May Be at Higher Risk for Urinary Tract Infections After Radical Hysterectomies
Patients with early-stage cervical cancer may have an increased risk of developing catheter-associated urinary tract infections following radical hysterectomies if they had a history of smoking or used catheters for more than 7 days postsurgery, according to a new study by Mercadel et al in the...
HPV Self-Collection Kits May Increase Cervical Cancer Screenings Among Underscreened, Underserved Patients
Researchers have found that mailing human papillomavirus (HPV) self-collection kits in addition to offering scheduling assistance to underscreened, underserved patients may increase the rate of cervical cancer screenings compared with scheduling assistance alone, according to a new study published...
Familial Clonal Hematopoiesis in Individuals With a Mutation in Telomere-Related Gene POT1
In a study reported in The New England Journal of Medicine, DeBoy et al found that individuals carrying germline heterozygous loss-of-function mutations in the telomere-related gene POT1 had long telomeres and may be at risk for benign and malignant neoplasms as part of a familial clonal...
President Biden Announces Intent to Nominate Monica M. Bertagnolli, MD, as Director of the NIH
In a statement released by The White House on May 15, President Joe Biden announced his intent to nominate Monica M. Bertagnolli, MD, as Director of the National Institutes of Health (NIH), the world’s preeminent biomedical research organization. As the statement makes clear, Dr. Bertagnolli is a...
Young Native Hawaiians and Pacific Islanders May Face Highest Rates of Cancer Mortality
Investigators have found that young Native Hawaiian and Pacific Islander patients may experience the highest rates of cancer mortality of any racial group in the United States among those aged 20 to 49 years. The new data were published by Haque et al in the Journal of the National Cancer...
Interruption of Adjuvant Endocrine Therapy to Attempt Pregnancy in Women With Breast Cancer
In a study reported in The New England Journal of Medicine, Ann H. Partridge, MD, MPH, and colleagues found that temporary interruption of adjuvant endocrine therapy to attempt pregnancy was not associated with an increased short-term risk of breast cancer events among women with hormone...
Lenalidomide in Previously Treated Children With Low-Grade Gliomas
In a Children’s Oncology Group phase II trial reported in the Journal of Clinical Oncology, Katherine E. Warren, MD, and colleagues found that lenalidomide showed activity in children with pilocytic astrocytomas and optic pathway gliomas who did not respond to initial therapy. As noted by the...
New Breast Cancer Screening Guidelines Call for Earlier, More Intensive Screenings for Women at High Risk
Updated recommendations from the American College of Radiology encouraged all women—particularly Black women and Ashkenazi Jewish women—to undergo risk assessments at 25 years of age to determine whether they may need breast cancer screenings earlier than age 40, according to new guidelines...
ARTISTRY-7 and ROSELLA: Phase III Trials to Evaluate Novel Agents in Platinum-Resistant Ovarian Cancer
Platinum resistance occurs in almost all patients whose ovarian cancer recurs. Single-agent chemotherapies are commonly used in this setting, but outcomes are generally poor, leaving a large unmet need for effective treatment. At the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on...
Final SORAYA Analysis Supports Mirvetuximab Soravtansine in Ovarian Cancer
Treatment with the folate receptor alpha (FRα)-targeted antibody-drug conjugate mirvetuximab soravtansine-gynx benefited patients with FRα-high, platinum-resistant ovarian cancer, even after multiple lines of prior therapy, according to an updated analysis of the SORAYA trial presented at the...
Expert Point of View: Rebecca Arend, MD, MSH and Ilaria Colombo, MD
“Endometrial cancer is the most frequently diagnosed gynecologic malignancy in the United States, and it is the only one where the mortality has actually risen over the past 40 years,” noted Rebecca Arend, MD, MSH, Associate Professor at the University of Alabama and Associate Scientist in the...
Checkpoint Inhibitors Poised to Change Standard of Care in Advanced Endometrial Cancer
The addition of a checkpoint inhibitor to standard chemotherapy as first-line treatment of advanced endometrial cancer reduced the risk of disease progression or death by 70% in patients with mismatch repair–deficient (dMMR) tumors in two recent phase III studies. The results of the two...
Detection of Early Emphysema During Lung Cancer Screening: Opportunities to Optimize Health
In an article in Annals of the American Thoracic Society, James L. Mulshine, MD, of the Center for Healthy Aging, Department of Medicine, Rush University, and colleagues maintained that the high frequency of emphysema newly identified during low-dose computed tomography (CT) lung cancer screening...
ASCO Releases Guideline Updates for Stage IV NSCLC With and Without Driver Alterations
ASCO has updated two living guidelines on the systemic treatment of stage IV non–small cell lung cancer (NSCLC) with and without driver alterations with the inclusion of new evidence-based treatment recommendations.1,2 Among the updates, the guidelines add the recently approved RAS GTPase family...
Novel Hormone Receptor–Driven Therapies Tackling Endocrine Resistance in Breast Cancer
In hormone receptor–positive metastatic breast cancer, tumors eventually become resistant not only to endocrine blockade but to inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6). This obstacle to successful treatment is being tackled with novel hormone receptor–directed therapies, with the...
